XUANZHUBIO-B (02575) saw its shares climb more than 5% during the morning trading session, last up 5.42% at HK$9.915, with turnover reaching HK$2.7797 million.

The company released its interim results for the six months ended June 30, 2026, reporting revenue of RMB 69.4 million, a significant increase of 288.1% year-on-year. According to the announcement, the revenue surge was primarily driven by higher sales volumes resulting from new product launches and the inclusion of products in the National Reimbursement Drug List (NRDL).

During the reporting period, the group advanced its business across four key fronts: commercial scaling, clinical development, early-stage research, and business development (BD), achieving solid overall progress. On the commercial side, the channel networks and academic recognition of its three marketed products continued to improve. In clinical development, several key studies for its core products reached important milestones. On the early-stage R&D front, the group expanded its technology platform capabilities and completed project initiation for multiple new programs. In the BD arena, the company made substantive breakthroughs in its globalization strategy through a dual approach of out-licensing and in-licensing.